A calcium channel blocker
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Mirogabalin

Item No. 22475

Technical Information
Formal Name
(1R,5S,6S)-6-(aminomethyl)-3-ethyl-bicyclo[3.2.0]hept-3-ene-6-acetic acid
CAS Number
1138245-13-2
Synonyms
  • DS-5565
Molecular Formula
C12H19NO2
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 0.5 mg/mlDMSO: 0.5 mg/mlEthanol: 0.5 mg/mlPBS (pH 7.2): 0.5 mg/ml
SMILES
CCC1=C[C@]([C@](CC(O)=O)(CN)C2)([H])[C@]2([H])C1
InChi Code
InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1
InChi Key
FTBQORVNHOIASH-CKYFFXLPSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Product Description

    Mirogabalin is a calcium channel blocker with analgesic effects.1 It binds to the α2δ-1 and α2δ-2 subunits of voltage-dependent Ca2+ channels. Mirogabalin has potent and sustained analgesic effects (ED50 = 2.5 mg/kg) in rats with diabetes induced by streptozotocin (STZ; Item No. 13104). Mirogabalin does not inhibit activities associated with CNS adverse effects of analgesics, such as rotarod performance (ID50 = 9.4 mg/kg) or locomotor activity (ID50 = 43.9 mg/kg), at its effective dose.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Brown, K., Ohwada, S., Warren, V., et al(405) A single ascending-dose study of mirogabalin in healthy subjects: Safety, tolerability, pharmacokinetic, and pharmacodynamic results. J. Pain 17(4S), S76 (2016).